Profitability
This table compares Peak Bio and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Peak Bio | N/A | N/A | -253.92% |
Peak Bio Competitors | -4,888.35% | -158.24% | -42.84% |
Earnings & Valuation
This table compares Peak Bio and its competitors top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Peak Bio | $370,000.00 | -$12.83 million | -0.33 |
Peak Bio Competitors | $549.58 million | -$36.47 million | -13.15 |
Peak Bio’s competitors have higher revenue, but lower earnings than Peak Bio. Peak Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
Risk and Volatility
Peak Bio has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Peak Bio’s competitors have a beta of 1.18, meaning that their average share price is 18% more volatile than the S&P 500.
Summary
Peak Bio beats its competitors on 6 of the 9 factors compared.
About Peak Bio
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.